My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Can-Fite Biopharma Ltd American Depositary Shares (NY:CANF)

3.320 +0.070 (+2.15%)

Streaming Delayed Price Updated: 1:18 PM EDT, May 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Can-Fite Biopharma Ltd American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 Next >

Can-Fite To Reveal Findings In Treatment Of Liver Cancer And Fibrosis With Cannabinoids At CannX ↗

March 11, 2022

Dr. Pnina Fishman CEO of Can-Fite BioPharma Ltd. (AMEX:CANF)...

Via Benzinga

Can-Fite BioPharma Flags Delay In Piclidenoson Data Readout From Psoriasis Study ↗

March 08, 2022

Citing unanticipated delay in the collection of study data, Can-Fite BioPharma Ltd (NYSE: CANF) said that the topline data from its Phase 3 Comfort study of Piclidenoson...

Via Benzinga

Psoriasis Drug Providers Looking Over Shoulders At Upcoming Competitor? ↗

February 03, 2022

Photo by Diana Polekhina on Unsplash

Via Benzinga

Can Fite Announces First Patient Enrolled in Phase IIb NASH Clinical Trial with Namodenoson

January 31, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

CAN-FITE ISSUES LETTER TO SHAREHOLDERS ↗

January 05, 2022

Q1 2022: Psoriasis Phase III Data & Commencement of Enrollment in Phase IIb NASH H1 2022: Commencement of Enrollment in Phase III Liver Cancer PETACH TIKVA,...

Via Benzinga

A New Oral Therapy for Psoriasis Could Be Coming Soon ↗

January 24, 2022

Photo by Towfiqu barbhuiya on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice...

Via Benzinga

Can Fite's Piclidenoson Destroys Pathological Skin Cells, Lab Study Shows ↗

January 13, 2022

Can-Fite BioPharma Ltd (NYSE: CANF) announced preclinical studies with skin cells, modeling psoriasis in humans, showing that Piclidenoson destroys pathological skin...

Via Benzinga

The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact ↗

January 13, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Says Lead Monoclonal Antibody Effective Against Omicron Variant Adagio...

Via Benzinga

PRIOR TO PHASE III PSORIASIS DATA RELEASE CAN FITE REPORTS THAT PICLIDENOSON DESTROYS PATHOLOGICAL SKIN CELLS IN VITRO ↗

January 13, 2022

Piclidenoson has been out-licensed for the indication of psoriasis in certain major markets PETACH TIKVA, Israel--(BUSINESS WIRE)-- Can-Fite BioPharma Ltd. (NYSE American:...

Via Benzinga

Prior to Phase III Psoriasis Data Release Can Fite Reports that Piclidenoson Destroys Pathological Skin Cells in vitro

January 13, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference ↗

January 10, 2022

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs...

Via Benzinga

Can-Fite to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference

January 10, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Issues Letter to Shareholders

January 05, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

FOLLOWING COMPLETE CLEARANCE OF CANCER LESIONS IN ADVANCED LIVER CANCER PATIENT, CAN-FITE IS FILING PATENT APPLICATIONS FOR THE TREATMENT OF VARIOUS ADVANCED SOLID TUMORS ↗

January 03, 2022

Namodenoson Headed into Pivotal Phase III Liver Cancer Study PETACH TIKVA, Israel--(BUSINESS WIRE)-- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a...

Via Benzinga

45 Biggest Movers From Yesterday ↗

December 30, 2021

Gainers Puxin Limited (NYSE: NEW) shares surged 80% to close at $0.54 on Wednesday after reporting results for the second quarter. United Time Technology Co., Ltd. (NASDAQ: UTME...

Via Benzinga

26 Stocks Moving In Wednesday's Mid-Day Session ↗

December 29, 2021

Gainers Puxin Limited (NYSE: NEW) jumped 100.5% to $0.6016 after reporting results for the second quarter. ShiftPixy, Inc. (NASDAQ: PIXY) climbed 38.4% to $1.55 after surging 43...

Via Benzinga

CANF Stock: The Cancer-Fighting News Sending Can-Fite Higher Today ↗

December 29, 2021

Can-Fite BioPharma is rising on Wednesday following positive Phase 2 data on its liver cancer treatment. Can it help turn CANF stock around?

Via InvestorPlace

Following Complete Clearance of Cancer Lesions in Advanced Liver Cancer Patient, Can-Fite is Filing Patent Applications for the Treatment of Various Advanced Solid Tumors

December 29, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

38 Stocks Moving In Tuesday's Mid-Day Session ↗

December 21, 2021

Gainers Reliance Global Group, Inc. (NASDAQ: RELI) surged 126% to $6.91 after gaining around 6% on Monday. Biofrontera Inc. (NASDAQ: BFRI) climbed 71.4% to $13.06 after gaining...

Via Benzinga

55 Biggest Movers From Yesterday ↗

December 22, 2021

Gainers Reliance Global Group, Inc. (NASDAQ: RELI) shares jumped 78.7% to close at $5.45 on Tuesday after gaining around 6% on Monday. Biofrontera Inc. (NASDAQ: BFRI) gained 44.8...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

December 21, 2021

Good morning, trader! We're kicking off the day with a dive into some of the biggest pre-market stock movers for Tuesday!

Via InvestorPlace

26 Stocks Moving in Tuesday's Pre-Market Session ↗

December 21, 2021

Gainers Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) rose 102% to $5.13 in pre-market trading after the company reported pan-coronavirus monoclonal antibody cocktail that retains...

Via Benzinga

65 Biggest Movers From Yesterday ↗

December 21, 2021

Gainers Society Pass Incorporated (NASDAQ: SOPA) shares climbed 240.2% to close at $11.26 on Monday after the company reported addition to the Russell 2000 Index. Bluerock...

Via Benzinga

Mid-Afternoon Market Update: Dow Tumbles 500 Points; Bluerock Residential Growth Shares Spike Higher ↗

December 20, 2021

Toward the end of trading Monday, the Dow traded down 1.42% to 34,862.49 while the NASDAQ fell 1.38% to 14,960.51. The S&P also fell, dropping 1.34% to 4,558.87. The U.S. has...

Via Benzinga

Can-Fite Shares Rally As Namodenoson Clears All Cancer Lesions In Liver Cancer Patient ↗

December 20, 2021

Can-Fite BioPharma Ltd (NYSE: CANF) announced that the last liver cancer patient treated under an Open-Label Extension program of its concluded Phase 2 study of Namodenoson...

Via Benzinga

Mid-Day Market Update: Crude Oil Drops Over 5%; Society Pass Shares Jump ↗

December 20, 2021

Midway through trading Monday, the Dow traded down 1.78% to 34,735.33 while the NASDAQ fell 1.43% to 14,952.69. The S&P also fell, dropping 1.59% to 4,547.26. The U.S. has the...

Via Benzinga

RKT Stock: 15 Things to Know as Rocket Moves Beyond Mortgages With Truebill Deal ↗

December 20, 2021

Rocket Companies (RKT) stock is on the move Monday following news of a $1.275 billion acquisition deal with Truebill.

Via InvestorPlace

CANF Stock Alert: The Liver Cancer News Catapulting Can-Fite BioPharma Shares Higher Today ↗

December 20, 2021

Can-Fite BioPharma (CANF) stock is rocketing higher on Monday thanks to new data from a Phase II clinical trial for liver cancer.

Via InvestorPlace

38 Stocks Moving In Monday's Mid-Day Session ↗

December 20, 2021

Gainers Society Pass Incorporated (NASDAQ: SOPA) shares jumped 120.9% to $7.31 after the company reported addition to the Russell 2000 Index. Can-Fite BioPharma Ltd. (NYSE: CANF...

Via Benzinga

Liver Cancer Patient Treated with Can-Fite’s Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study

December 20, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.